DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/fkgxr3/metastatic) has announced the addition of the "Metastatic Biliary Tract Cancer - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Biliary Tract Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Biliary Tract Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AstraZeneca PLC
- GlaxoSmithKline plc
- Novartis AG
- OncoTherapy Science, Inc.
- (dabrafenib mesylate + trametinib dimethyl sulfoxide)
- selumetinib sulfate
- trametinib dimethyl sulfoxide
For more information visit http://www.researchandmarkets.com/research/fkgxr3/metastatic